Sunshine Biopharma (SBFM) Competitors $1.41 -0.03 (-2.08%) Closing price 08/1/2025 03:58 PM EasternExtended Trading$1.41 0.00 (-0.07%) As of 08/1/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SBFM vs. CING, NNVC, QTTB, TENX, FBLG, LGVN, RVPH, CYCC, ASBP, and AYTUShould you be buying Sunshine Biopharma stock or one of its competitors? The main competitors of Sunshine Biopharma include Cingulate (CING), NanoViricides (NNVC), Q32 Bio (QTTB), Tenax Therapeutics (TENX), FibroBiologics (FBLG), Longeveron (LGVN), Reviva Pharmaceuticals (RVPH), Cyclacel Pharmaceuticals (CYCC), Aspire Biopharma (ASBP), and Aytu BioPharma (AYTU). These companies are all part of the "pharmaceutical products" industry. Sunshine Biopharma vs. Its Competitors Cingulate NanoViricides Q32 Bio Tenax Therapeutics FibroBiologics Longeveron Reviva Pharmaceuticals Cyclacel Pharmaceuticals Aspire Biopharma Aytu BioPharma Sunshine Biopharma (NASDAQ:SBFM) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends. Which has more volatility & risk, SBFM or CING? Sunshine Biopharma has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.75, indicating that its share price is 175% less volatile than the S&P 500. Does the media prefer SBFM or CING? In the previous week, Cingulate had 1 more articles in the media than Sunshine Biopharma. MarketBeat recorded 3 mentions for Cingulate and 2 mentions for Sunshine Biopharma. Cingulate's average media sentiment score of 0.82 beat Sunshine Biopharma's score of -0.50 indicating that Cingulate is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sunshine Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Cingulate 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is SBFM or CING more profitable? Cingulate has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -13.88%. Sunshine Biopharma's return on equity of -21.25% beat Cingulate's return on equity.Company Net Margins Return on Equity Return on Assets Sunshine Biopharma-13.88% -21.25% -16.89% Cingulate N/A -229.78%-142.28% Do insiders and institutionals believe in SBFM or CING? 42.0% of Sunshine Biopharma shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 0.1% of Sunshine Biopharma shares are owned by company insiders. Comparatively, 5.3% of Cingulate shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has preferable earnings and valuation, SBFM or CING? Sunshine Biopharma has higher revenue and earnings than Cingulate. Cingulate is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSunshine Biopharma$34.87M0.18-$5.13M-$150.88-0.01CingulateN/AN/A-$15.55M-$8.48-0.60 Do analysts rate SBFM or CING? Sunshine Biopharma currently has a consensus target price of $15.00, indicating a potential upside of 963.83%. Cingulate has a consensus target price of $26.00, indicating a potential upside of 409.80%. Given Sunshine Biopharma's higher possible upside, research analysts clearly believe Sunshine Biopharma is more favorable than Cingulate.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sunshine Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Cingulate 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummarySunshine Biopharma beats Cingulate on 8 of the 14 factors compared between the two stocks. Get Sunshine Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SBFM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SBFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBFM vs. The Competition Export to ExcelMetricSunshine BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.42M$3.02B$5.53B$9.37BDividend YieldN/A2.44%4.74%4.12%P/E Ratio-0.0117.6228.8823.79Price / Sales0.18309.96440.8796.30Price / CashN/A41.6335.0757.18Price / Book0.158.488.255.54Net Income-$5.13M-$55.06M$3.25B$259.88M7 Day Performance-9.62%-3.99%-3.75%-4.67%1 Month Performance-14.55%9.58%4.26%4.40%1 Year Performance502.82%6.70%25.83%17.91% Sunshine Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBFMSunshine Biopharma1.7121 of 5 stars$1.41-2.1%$15.00+963.8%+456.0%$6.42M$34.87M-0.013Short Interest ↑CINGCingulate3.1942 of 5 stars$5.26+0.7%$26.00+394.8%+1,408.9%$27.48MN/A-0.6320NNVCNanoViricides0.6555 of 5 stars$1.69-0.6%N/A-24.8%$27.16MN/A-2.3520QTTBQ32 Bio1.6281 of 5 stars$2.13-4.4%$12.17+470.9%-94.7%$27.07MN/A-0.4539Upcoming EarningsShort Interest ↑TENXTenax Therapeutics1.3154 of 5 stars$6.03-0.3%$17.50+190.2%+94.4%$25.79MN/A-2.519FBLGFibroBiologics3.1008 of 5 stars$0.63-4.4%$13.00+1,973.4%-87.1%$25.75MN/A-3.0910News CoverageEarnings ReportUpcoming EarningsAnalyst ForecastLGVNLongeveron2.2837 of 5 stars$1.64+0.2%$8.67+427.5%-46.2%$25.01M$2.39M-0.2720Negative NewsShort Interest ↑Gap DownRVPHReviva Pharmaceuticals2.8426 of 5 stars$0.46-5.7%$9.00+1,848.1%-59.3%$24.29MN/A-0.645Short Interest ↑CYCCCyclacel Pharmaceuticals0.2478 of 5 stars$14.53-5.6%N/A-97.6%$23.79M$40K-0.0214Negative NewsShort Interest ↑Gap DownASBPAspire BiopharmaN/A$0.48-0.2%N/AN/A$23.77MN/A0.00N/AAYTUAytu BioPharma3.1649 of 5 stars$2.61-0.7%$10.00+282.8%-8.0%$23.54M$81M-3.64160 Related Companies and Tools Related Companies CING Competitors NNVC Competitors QTTB Competitors TENX Competitors FBLG Competitors LGVN Competitors RVPH Competitors CYCC Competitors ASBP Competitors AYTU Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SBFM) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sunshine Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sunshine Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
